Researchers identify potential FOP biomarkers
US researchers have identified three plasma-soluble biomarkers that may reflect acute and chronic inflammatory states in people with fibrodysplasia ossificans progressiva (FOP).
Senolytics may have a role to play in FOP treatment
Drugs that selectively induce apoptosis of senescent cells may be effective candidates for the treatment of fibrodysplasia ossificans progressiva (FOP) flare-ups via the inhibition of tissue reprogramming and subsequent prevention of endochondral heterotopic ossification (HO), preclinical study findings indicate.
US FOP prevalence higher than expected
The prevalence of fibrodysplasia ossificans progressiva (FOP) in the US is higher than previously believed, according to research published in the Orphanet Journal of Rare Diseases.
Anecdotal evidence supports further study of imatinib in children with FOP
Children treated for fibrodysplasia ossificans progressiva (FOP) with imatinib in an off-on-off-on (O4) regimen have fewer flare-ups, decreased swelling, and improved function when on versus off treatment, US researchers report.
ASBMR 2020: Garetosmab and palovarotene show promise in FOP
Results of two trials presented at the ASBMR 2020 Annual Meeting Virtual Event show promising new options for the treatment of fibrodysplasia ossificans progressiva (FOP).
ASBMR 2020: Misdiagnosis common in fibrodysplasia ossificans progressiva
Patients with fibrodysplasia ossificans progressiva (FOP) wait an average of 1.5 years to receive a correct diagnosis, with more than half initially misdiagnosed, show data from the international FOP registry.